Drug intelligence / Profile preview

osteoprotegerin

Development stage: Unknown
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

Osteoprotegerin (OPG) is a cytokine receptor of the tumor necrosis factor (TNF) receptor superfamily that functions as a decoy receptor for RANKL (receptor activator of nuclear factor kappa-B ligand). It inhibits osteoclast formation and activity, thereby blocking bone resorption. OPG also binds to TRAIL (TNF-related apoptosis-inducing ligand) and inhibits TRAIL-induced apoptosis. It plays critical roles in bone metabolism regulation and has been investigated as a potential therapeutic for osteoporosis, cancer-induced bone disease, hypercalcemia of malignancy, and vascular disorders.

Other names: osteoclastogenesis inhibitory factortumour necrosis factor receptor superfamily member 11B

Targets

RANKL (Receptor Activator for Nuclear Factor-kappa B Ligand)TNFSF10 (Tumour necrosis factor-related apoptosis-inducing ligand)

Beyond the preview

Go deeper on osteoprotegerin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on osteoprotegerin.